apixaban
Profits fall at Bayer but new drugs see growth
May 1, 2015Sales and Marketing Bayer, Eliquis, Eylea, Renegeron, Xarelto, apixaban
Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …
Anti-blood clotting drug Eliquis gets NICE nod
March 6, 2015Sales and Marketing BMS, DVT, Eliquis, NICE, Pfizer, Pradaxa, apixaban, clotting
Bristol-Myers Squibb and Pfizer’s Eliquis for preventing blood clots has been shown the green light to treat venous thromboembolism (VTE), …
Pfizer posts fourth-quarter revenue decline
January 28, 2015Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate
Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …
Pradaxa and Eliquis gain trial boost over warfarin
August 31, 2011Sales and Marketing Eliquis, Pradaxa, Xarelto, apixaban
A pair of new blood thinners are superior to warfarin when it comes to reducing the risk of stroke in …
Pfizer and BMS to give Eliquis a rolling launch in Europe
May 24, 2011Sales and Marketing Eliquis, Pfizer, apixaban, atrial fibrillation
Pfizer and Bristol-Myers Squibb are gearing up to give their new oral anticoagulant Eliquis a rolling launch in Europe, starting …
Pfizer and BMS’ blood thinner Eliquis approved in Europe
May 23, 2011Sales and Marketing BMS, Eliquis, Pfizer, apixaban
Pfizer and Bristol-Myers Squibb’s eagerly anticipated blood thinner Eliquis has gained European approval. A twice-daily oral Factor Xa inhibitor, Eliquis …
Companies join forces to promote AF awareness
February 16, 2011Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation
Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …
VTE trial boost for Pfizer and BMS’ apixaban
December 31, 2010Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism
Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …
Apixaban trial for ACS abandoned
October 20, 2010Sales and Marketing ACS, BMS, Pfizer, apixaban
Pfizer and Bristol-Myers Squibb have halted a trial of their heart drug apixaban after signs of increased risk of …
Pradaxa, Xarelto and apixaban vie for attention
September 6, 2010Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation
New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …
Novel anticoagulants set to lead atrial fibrillation market
July 9, 2010Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation
Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …
Early halt for successful apixaban trial
June 14, 2010Research and Development apixaban, atrial fibrilation
Pfizer and Bristol-Myers Squibb’s atrial fibrillation treatment apixaban has performed so well in a phase III trial that it has …
Study boost for atrial fibrillation drugs
March 17, 2010Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban
Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …
Phase III success for apixaban
March 5, 2010Research and Development BMS, Pfizer, VTE, apixaban
Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …
BMS and Pfizer will file apixaban in Europe next year
December 8, 2009Sales and Marketing BMS, Pfiizer, Pfizer, VTE, apixaban
Bristol-Myers Squibb and Pfizer are to submit their new anti-clotting drug for European approval in the first half of next …
Latest content
Five Facts about cardiovascular disease
